NASDAQ:LQDA
Liquidia Technologies Inc. Stock News
$12.71
-0.0300 (-0.235%)
At Close: May 17, 2024
Liquidia to Report Third Quarter 2020 Financial Results and Provide Corporate Update on November 6, 2020
04:15pm, Friday, 30'th Oct 2020
Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET Company to Host Webcast and Conference Call November 9, 2020 at 8:00p.m. ET
Liquidia Technologies (LQDA) Investor Presentation - Slideshow
06:10pm, Thursday, 13'th Aug 2020
The following slide deck was published by Liquidia Technologies, Inc. in conjunction with this event..
Liquidia Reports Second Quarter 2020 Financial Results and Provides Corporate Update
11:15am, Monday, 10'th Aug 2020
Received FDA Acceptance of LIQ861 NDA for Review Reported Final Safety and Tolerability Results for LIQ861 INSPIRE Trial Appointed Tushar Shah, M.D. as Chief Medical Officer Announced Definitive Ag
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
IPO Update: PainReform Readies U.S. IPO Plan (Pending:PRFX)
06:25pm, Thursday, 06'th Aug 2020
PainReform has filed to raise $23 million in a U.S. IPO.
Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
09:30pm, Wednesday, 05'th Aug 2020
RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializ
Liquidia Releases Exploratory Endpoint Data from INSPIRE Study at the American Thoracic Society (ATS) Annual Meeting
11:15am, Wednesday, 05'th Aug 2020
New data from INSPIRE LIQ861 safety and tolerability study in pulmonary arterial hypertension (PAH) patients demonstrate positive trends in exploratory endpoints, including quality of life (QoL)RESEAR
Liquidia to Report Second Quarter 2020 Financial Results and Provide Corporate Update on August 10, 2020
01:20pm, Monday, 03'rd Aug 2020
RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq:LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializat
Liquidia Responds to United Therapeutics Corporation Lawsuit Alleging Infringement of New Tyvaso Patent
01:08pm, Friday, 24'th Jul 2020
RESEARCH TRIANGLE PARK, N.C., July 24, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercializ
Comparing Globus Medical (NYSE:GMED) and Liquidia Technologies (NYSE:LQDA)
01:38am, Sunday, 19'th Jul 2020
Liquidia Technologies (NASDAQ:LQDA) and Globus Medical (NYSE:GMED) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their insti
-$0.39 Earnings Per Share Expected for Liquidia Technologies Inc (NASDAQ:LQDA) This Quarter
05:30am, Tuesday, 14'th Jul 2020
Equities research analysts expect Liquidia Technologies Inc (NASDAQ:LQDA) to announce earnings of ($0.39) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provi
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating whether the following mergers are fair to shareholders. Halper Sadeh LLP may seek increased consideration, additional
Liquidia Announces Closing of Public Offering of Common Stock
08:01pm, Thursday, 02'nd Jul 2020
Liquidia Technologies, Inc. (LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, announ
Liquidia Announces Closing of Public Offering of Common Stock
12:00am, Thursday, 02'nd Jul 2020
RESEARCH TRIANGLE PARK, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical...
